Annex I
United Kingdom
| Further details on the identity and specification of the active substance are provided in the review report. | |||||
| Common Name, Identification Numbers | IUPAC Name | Purityf1 | Date of approval | Expiration of approval | Specific provisions |
|---|---|---|---|---|---|
| Bentazone CAS No 25057-89-0 CIPAC No 366 | 3-isopropyl-1H-2,1,3-benzothiadiazin-4(3H)-one 2,2- dioxide | ≥ 960 g/kg 1,2-dichloroethane < 3 mg/kg | 1 June 2018 | 31 May 2025 | For the implementation of the uniform principles, as referred to in Article 29(6) of Regulation (EC) No 1107/2009, the conclusions of the review report on bentazone, and in particular Appendices I and II thereof, shall be taken into account. In their overall assessment Member States shall pay particular attention to:
Conditions of use shall include risk mitigation measures, where appropriate. The applicant shall submit by 1 February 2019 to the Commission, the Member States and the Authority confirmatory information as regards Level 2/3 tests as currently indicated in the OECD Conceptual Framework investigating the potential for endocrine-mediated effects of bentazone. |
Annotations
Footnotes
- f1
-
Further details on the identity and specification of the active substance are provided in the review report.